Submit a Complete Response Letter.
Five intake fields, then a named-role confirmation gate. We read every finalized submission directly — no sales qual maze, no auto-responder.
What is a CRL?
A regulator letter, not a refusal.
A Complete Response Letter (CRL) is what the FDA sends when an application — IND, NDA, BLA, or 510(k) — has been reviewed and the Agency cannot approve it in its current form. The letter cites the specific deficiencies that must be addressed before the application can move forward.
A CRL is not a refusal-to-file and not a clinical hold. It is the Agency's working response: here is what is missing, here is what is unclear, here is the additional information we need. The sponsor answers with a Complete Response — a resubmission that addresses each cited deficiency with supporting data, analyses, or labelling updates.
The resubmission is a regulated deliverable in its own right. Every cited deficiency needs to be acknowledged, every intended response needs to map back to a specific CRL paragraph, and the package — cover letter, supporting analyses, updated sections, forms — has to arrive together, on the FDA-prescribed timeline for the submission type.
The reviewer who picks this up wants to see the submission reference on the CRL header (so the proper eCTD sequence is in scope), the severity of the cited deficiencies (so the engagement is sized correctly), and a one-paragraph description of what your team plans to include in the response — enough that the reviewer can scope the work before any document is exchanged.
For the audit-grade posture behind every CRL engagement, see our compliance posture — five engagement documents (BAA, SOPs, validation log, access matrix, change-control log) that hold every reviewer-signed deliverable to the same standard.
Intake form
Submission details.
All intake fields are required. The reviewer will reach back within two business days after both named sign-offs are recorded.